^
Association details:
| Biomarker: | NPAP1 mutation + TMB-H |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | Immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
NPAP1 mutation as an indicator stratified patients benefit from immune checkpoint inhibitors in NSCLC.
Published date:
05/26/2022
Excerpt:
NSCLC patients with NPAP1 mutation were significantly associated with better PFS (HR = 0.37; 95% CI, 0.19-0.71; P = 0.002), objective response rate (ORR, 54.2% vs 28.4%; P = 0.048) and durable clinical benefit (DCB, 75.0% vs 42.6%; P= 0.003) after ICIs therapy, compared with those with wide-type NPAP1. NPAP1 mutation were associated with increased TMB (P< 0.001).
DOI:
10.1200/JCO.2022.40.16_suppl.e14574
